Therapeutic Uses and Supportive Benefits of Citrocalcio

Citrocalcio is commonly used to help with symptoms related to systemic imbalance, providing supportive relief. It is often used when short-term symptomatic assistance is needed for conditions involving episodic or fluctuating manifestations.

The product is applied in clinical settings that involve acute or unstable symptom patterns, such as symptoms that create noticeable physiological strain or interfere with daily functioning. It helps manage symptoms associated with systemic or localized discomfort, including those linked to conditions where functional stability becomes affected. It is often used when symptoms intensify, providing support that helps ease the overall symptom burden. As noted in its therapeutic function, “it contributes to improved comfort during periods of heightened symptoms.”

Quick Fact: Supportive Symptom Management
Citrocalcio is commonly used to help with symptom clusters that may become intense or disruptive, and offers symptomatic relief that helps patients cope more steadily.

Regulatory References

1. Calcium supplements: MedlinePlus Medical Encyclopedia

The use of Citrocalcio (Calcium Citrate and Dihydrotachysterol) is strictly defined by regulatory guidelines, primarily focusing on conditions related to calcium metabolism.

Populations For Whom Use is Contraindicated

Use is absolutely prohibited for patients diagnosed with hypercalcemia (abnormally high blood calcium) or hypervitaminosis D (Vitamin D toxicity). Individuals with known hypersensitivity to any component or those with metastatic calcification or uncontrolled hypercalciuria must not use this medicine.

Populations Requiring Conditional Use

Patients with severe renal impairment should use the medicine only under strict monitoring due to the high risk of calcification. Conditional use is also necessary for those with a history of calcium kidney stones or sarcoidosis.

Age and Physiological Status Eligibility

The medicine is generally intended for use in adults. In some regions, fixed-dose formulations are not recommended or contraindicated in the pediatric population (children and adolescents). For pregnancy, use is restricted to situations where the potential benefit clearly justifies the potential risk (classified as Pregnancy Category C). Use is not recommended during breastfeeding.

Interactions with other medicines and products

Citrocalcio (Calcium Citrate and Dihydrotachysterol) has officially documented interaction patterns that are classified based on pharmacodynamic risk and altered systemic exposure of co-administered agents.

Co-administration is contraindicated with certain drug classes. This includes Cardiac Glycosides (such as Digoxin) due to a significantly increased risk of ventricular arrhythmias resulting from elevated calcium levels. Combining Citrocalcio with other Vitamin D Analogs is also prohibited because of the documented risk of additive hypercalcemic effects.

Several agents are documented to modify the components' exposure. Thiazide Diuretics are associated with a pharmacodynamic interaction that elevates calcium levels by reducing its renal clearance. Conversely, Bile Acid Sequestrants and Mineral Oil are documented to reduce the serum concentration of the Dihydrotachysterol component. Additionally, CYP3A4 inhibitors (like Grapefruit Juice) are documented to alter the plasma concentrations of the Vitamin D analog.

The calcium component decreases the absorption of numerous co-administered agents, including Tetracycline and Quinolone/Fluoroquinolone Antibiotics, and Bisphosphonates. Regulatory information mandates a separation of administration time for the calcium component and these antibiotics to prevent decreased bioavailability. Similarly, a separation of at least two hours is required from foods high in Oxalic or Phytic Acid to maintain optimal calcium absorption. The risk of these interactions is heightened in populations with impaired renal function.

Citrocalcio, comprised of calcium citrate and cholecalciferol (Vitamin D3), modulates systemic calcium homeostasis through two primary components. Calcium citrate dissociates in the gastrointestinal tract, liberating Ca^2+ ions for absorption, primarily via paracellular transport, thereby increasing the plasma concentration of ionized calcium. This elevated Ca^2+ concentration acts as an agonist on the Extracellular Calcium-Sensing Receptor (CaSR) located on the surface of parathyroid gland cells.

The CaSR activation triggers an intracellular pathway involving G-proteins, leading to a dose-dependent inhibition of Parathyroid Hormone (PTH) secretion. Reduced PTH signaling modulates renal and skeletal calcium flux. Simultaneously, cholecalciferol is sequentially hydroxylated in the liver and kidney to its active form, 1,25-dihydroxyvitamin D3 (calcitriol). This secosteroid acts as a ligand for the nuclear Vitamin D Receptor (VDR), forming a heterodimer with the Retinoid X Receptor (RXR). The VDR/RXR complex functions as a transcription factor, binding to Vitamin D-Response Elements (VDREs) in the genome of intestinal enterocytes. This transcriptional modulation enhances the expression of key calcium transport proteins, including TRPV6 (Transient Receptor Potential Cation Channel Subfamily V Member 6) and Calbindin, leading to augmented transcellular absorption of Ca^2+ from the small intestine. The net systemic physiological consequence is a shift in calcium balance, favoring increased Ca^2+ availability for deposition into the skeletal matrix.

How to use Citrocalcio: Official Administration Guidelines

This section outlines the standardized usage of Citrocalcio, based on the established profiles for its components, Dihydrotachysterol (DHT) and Calcium Citrate.

---

Administration Scope

Feature	Guideline
Route of administration	The approved route for this medicine is Oral (tablets or solution).
Dosing schedule	The regimen is dual-component: DHT is started with a loading dose (0.8 mg to 2.4 mg daily) followed by a maintenance dose (0.2 mg to 1.0 mg daily). Required elemental calcium intake is typically 1 g to 1.5 g daily.
Frequency and schedule	The overall regimen is a divided-dose schedule. The DHT component is generally taken once daily, while the total calcium dose is divided into smaller administrations throughout the day.
Timing in relation to meals	Administration with food is recommended to maximize absorption efficiency, particularly when elemental calcium doses are less than or equal to 500 mg.
Age-group administration	Specific initial and maintenance dose ranges are established for pediatric use, including doses for neonates and infants.
Special procedural conditions	The dose is not fixed and mandates periodic titration based on regular serum calcium determinations to maintain the targeted range of 9 mg/dL to 10 mg/dL. Titration is typically performed in 4 to 8 week intervals.

---

Resulting Procedural Structure

Official step sequence:

• Initiate the regimen using the higher loading dose of Dihydrotachysterol for the prescribed initial period.
• Administer the total daily dose according to a divided daily schedule, optimizing the timing of the calcium component with meals.
• Perform regular laboratory assessments of serum calcium to precisely guide the need for subsequent dose adjustments.
• Titrate the daily dose of Dihydrotachysterol based on the resulting laboratory values to maintain the targeted calcium range, using the established 4 to 8 week interval for adjustments.

Connection to the overall use protocol (2–4 sentences):

The standardized administration protocol follows a structured, two-phase dosing approach that transitions from an initial loading phase to long-term maintenance. This protocol is designed to ensure accurate and controlled oral use, requiring both a divided daily schedule and laboratory-guided dose adjustments.

Research evidence / Overview of studies for Citrocalcio

This section describes the types of research that has explored Citrocalcio's components, the populations observed in those studies, and the patterns of findings that were reported, without providing clinical advice or implying certainty of results.

---

Evidence for Calcium Regulation in Specific Metabolic Conditions

Research for this combination was evaluated in patient groups dealing with a severe deficiency of the body's natural mineral-regulating hormone, such as those with chronic hypoparathyroidism. This approach uses Calcium Citrate alongside Dihydrotachysterol (DHT), a specialized Vitamin D analog used in research when natural regulatory pathways may be impaired.

Short-term RCTs (Randomized Controlled Trials), often involving modest sample sizes, explored the use of Calcium Citrate and monitored biomarkers like serum calcium, phosphorus, and PTH concentrations. Researchers examined outcomes related to systemic imbalance, specifically focusing on how different calcium salts might affect markers related to the risk of nephrolithiasis (kidney stone formation) and gastrointestinal tolerability. The overall research describes that while studies reported monitoring urinary risk markers, data show patterns related to monitoring similar overall levels of serum calcium and PTH between different forms.

---

Evidence for General Bone Health Support

The general therapeutic purpose of this preparation was studied in research examining outcomes related to bone mineral status. This evidence is primarily drawn from Systematic Reviews and Meta-analyses of multiple large-scale intervention trials involving the general class of calcium and vitamin D supplementation.

Studies observed the use of the general class in postmenopausal women and older adults. The research examined outcomes related to Bone Mineral Density (BMD) at sites like the spine and hip. Findings describe patterns where supplementation was associated with measured shifts in BMD. However, when research examined fracture incidence, the reported patterns were mixed, and certainty remains low on large-scale risk reduction.

---

Research Limitations and Uncertainty

Studies explored the use of the DHT component in long-term observational settings (sometimes decades). These studies documented findings associated with the occurrence of renal calcifications over extended periods and indicated that high blood calcium events associated with DHT may persist for a longer duration. Follow-up durations were limited in direct comparative trials of Calcium Citrate, meaning there is limited information for long-term outcomes. Data for certain groups, such as pediatric and adolescent cohorts, remain insufficient regarding the specific combination.

Key Studies & References

1. Calcium supplements: MedlinePlus Medical Encyclopedia
2. A Systematic Review of Treatment for Hypoparathyroidism

The official storage and disposal guidelines for Citrocalcio (a combination of Calcium Citrate and Dihydrotachysterol) are mandated to protect the product's stability and ensure safety.

Item	Requirement Statement
Labeled storage temperature:	Store at Controlled Room Temperature, typically 15 C to 30 C (59 F to 86 F).
Light/moisture protection:	Must be protected from light and kept in a cool, dry environment.
Packaging rules:	Keep the medicine in a tight, light-resistant container and ensure the container remains tightly closed.
Child-protection storage:	Must be stored locked up and kept out of the reach of children for safety.
Disposal instructions:	Dispose of contents and container in accordance with local regulations; do not let the product enter drains or sewer systems.

The regulatory profile mandates maintaining a defined temperature range and strictly protecting the product from light and moisture to prevent degradation. The labeling requires the medicine to be stored securely (locked up) and instructs that disposal must prevent environmental contamination, utilizing established hazardous or special waste methods.